» Articles » PMID: 15901925

Sulforhodamine B Assay and Chemosensitivity

Overview
Journal Methods Mol Med
Specialty Molecular Biology
Date 2005 May 20
PMID 15901925
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

The sulforhodamine B (SRB) assay was developed by Skehan and colleagues to measure drug-induced cytotoxicity and cell proliferation for large-scale drug-screening applications. Its principle is based on the ability of the protein dye sulforhodamine B to bind electrostatically and pH dependent on protein basic amino acid residues of trichloroacetic acid-fixed cells. Under mild acidic conditions it binds to and under mild basic conditions it can be extracted from cells and solubilized for measurement. Results of the SRB assay were linear with cell number and cellular protein measured at cellular densities ranging from 1 to 200% of confluence. Its sensitivity is comparable with that of several fluorescence assays and superior to that of Lowry or Bradford. The signal-to-noise ratio is favorable and the resolution is 1000-2000 cells/well. It performed similarly compared to other cytotoxicity assays such as MTT or clonogenic assay. The SRB assay possesses a colorimetric end point and is nondestructive and indefinitely stable. These practical advances make the SRB assay an appropriate and sensitive assay to measure drug-induced cytotoxicity even at large-scale application.

Citing Articles

Green synthesis of silver nanoparticles using leaf extracts: preparation, physicochemical characterization and ameliorative effect against human cancer cell lines.

Konappa N, Patil R, Kariyappa A, Krishnamurthy S, Ramachandrappa N, Krishnappa R Cytotechnology. 2024; 77(1):16.

PMID: 39669689 PMC: 11631834. DOI: 10.1007/s10616-024-00674-7.


New Skin-Relevant Cell Coculture Model With Stratum Corneum-Like Layer.

Quijas G, Lewinska A, Lukaszewicz M, Bojanowski K Biomed Res Int. 2024; 2024:1041392.

PMID: 38933176 PMC: 11208096. DOI: 10.1155/2024/1041392.


XPA tumor variant leads to defects in NER that sensitize cells to cisplatin.

Blee A, Gallagher K, Kim H, Kim M, Kharat S, Troll C NAR Cancer. 2024; 6(1):zcae013.

PMID: 38500596 PMC: 10946055. DOI: 10.1093/narcan/zcae013.


Disparities in Cisplatin-Induced Cytotoxicity-A Meta-Analysis of Selected Cancer Cell Lines.

Cwiklinska-Jurkowska M, Wiese-Szadkowska M, Janciauskiene S, Paprocka R Molecules. 2023; 28(15).

PMID: 37570731 PMC: 10421281. DOI: 10.3390/molecules28155761.


Fabrication and optimization of itraconazole-loaded zein-based nanoparticles in coated capsules as a promising colon-targeting approach pursuing opportunistic fungal infections.

Adel S, Fahmy R, Elsayed I, Mohamed M, Ibrahim R Drug Deliv Transl Res. 2023; 13(12):2982-3002.

PMID: 37270444 PMC: 10624751. DOI: 10.1007/s13346-023-01365-0.